Semaglutide

At a glance

What is semaglutide?

Semaglutide is a synthetic peptide drug that mimics GLP-1 (glucagon-like peptide-1), a hormone your gut naturally releases after eating. It's a 31-amino-acid chain engineered with three specific modifications that extend its half-life from about 2 minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing.^[6]

Developed by Novo Nordisk in Denmark, semaglutide emerged from a systematic program that tested hundreds of GLP-1 analogs. It was compound #217 in that program. The three modifications that make it work are:

• Aib at position 8: Protects against DPP-4 enzyme degradation (what normally destroys GLP-1 in minutes)
• Arg at position 34: Prevents fatty acid binding at an unintended site
• C-18 fatty diacid at Lys26: Enables strong albumin binding, which acts as a slow-release reservoir in the blood

The result is a drug that does what natural GLP-1 does — stimulate insulin release, suppress glucagon, slow stomach emptying, and reduce appetite — but lasts long enough to be clinically useful.

Semaglutide is sold under three brand names: Ozempic (injectable, for type 2 diabetes), Wegovy (injectable and oral, for weight management and MASH), and Rybelsus (oral, for type 2 diabetes). It became a household name around 2022-2023 as its weight loss effects gained widespread media attention.

How it works

In plain terms, semaglutide tells your body three things: release more insulin (but only when blood sugar is already high), slow down digestion so you feel full longer, and reduce appetite signals in the brain. The net effect is lower blood sugar, less hunger, and significant weight loss.

What the research says

Semaglutide has been studied in more than 100 clinical trials with over 25,000 participants in pivotal Phase III programs alone. The evidence for its efficacy in weight loss, glycemic control, and cardiovascular risk reduction is among the strongest in modern medicine.

Research timeline

Semaglutide's research timeline reads like a case study in rigorous drug development — from discovery through multiple FDA approvals and indication expansions:

Key clinical trials

The sheer scale of semaglutide's clinical program is unusual — even among FDA-approved drugs. Here are the most important trials:

Emerging research

Active clinical trials are exploring semaglutide for indications beyond its current approvals:

What the evidence shows

Unlike most peptides profiled on Peptide Garden, the claims about semaglutide are largely supported by strong clinical evidence. Here's the evidence behind the most common questions:

Safety & side effects

Semaglutide's safety profile is well-characterized from thousands of patients across dozens of trials, plus post-marketing data from millions of prescriptions. The risks are real — but they are known, documented, and manageable under medical supervision.^[7]

Common side effects (from clinical trials)

Gastrointestinal effects are the most common and are dose-dependent:

• Nausea: 20-44% (vs. ~10% placebo) — typically worst during dose escalation, improves over 4-8 weeks
• Diarrhea: 15-30%
• Vomiting: 5-24%
• Constipation: 10-24%
• Abdominal pain: 5-20%

Other reported side effects include injection-site reactions, headache, fatigue, dizziness, and dyspepsia.

Serious safety concerns

• Pancreatitis: Rare but documented. GLP-1 RA users show approximately 2x risk vs. non-users in pharmacovigilance data. Contraindicated in patients with history of pancreatitis.
• Gallbladder disease: Increased risk of cholelithiasis (gallstones), confirmed across multiple trials.
• Acute kidney injury: Reported, likely secondary to dehydration from severe GI side effects. Adequate hydration is essential.
• Diabetic retinopathy: SUSTAIN 6 showed higher rate of retinopathy complications in patients with pre-existing retinopathy.
• Pulmonary aspiration during anesthesia: Since November 2024, the FDA label carries a class-wide warning about the risk of pulmonary aspiration under general anesthesia or deep sedation, because delayed gastric emptying can leave food in the stomach. Anesthesiology societies (not the FDA label) recommend holding the drug before such procedures. Tell your surgical and anesthesia team you take semaglutide.^[15]
• Gastrointestinal obstruction: Postmarketing GI adverse reactions on the label include ileus, intestinal obstruction, and severe constipation or fecal impaction.^[15]
• Muscle/lean mass loss: 25-40% of weight lost is lean mass. This is a meaningful concern, especially for older adults at risk of sarcopenia.^[12] A 2026 consensus statement from the European Association for the Study of Obesity, the European Federation of the Associations of Dietitians and the European Coalition for People living with Obesity sets out practical nutrition, physical-function and psychological guidance for people on incretin therapy — the best guideline-grade anchor currently available for managing this.^[37]
• Hair loss (alopecia) — a new signal, not a confirmed effect: Hair thinning on GLP-1 drugs has been an anecdotal, forum-level complaint for years. In July 2026 it got its first serious study: a BMJ target trial emulation in adults with type 2 diabetes found higher rates of diagnosed alopecia after starting a GLP-1 agonist than after starting an SGLT-2 inhibitor (HR 1.37, 95% CI 1.08–1.73) or a DPP-4 inhibitor (HR 1.68, 1.28–2.20), with the association strongest for non-scarring alopecia. Take that seriously and in proportion: it is a single health system, type 2 diabetes only, the outcome is a diagnostic code rather than a dermatology exam, and the authors report the effect attenuates after negative-control calibration. Substantial weight loss from any cause — surgery, dieting, illness — can trigger telogen effluvium, a temporary shedding phase that usually resolves. This study cannot tell those apart. If you notice hair shedding, it is worth raising with your prescriber, and worth checking iron, thyroid and protein intake rather than assuming the drug is the cause.^[30]
• Suicidal ideation — review resolved, no increased risk found: An early signal in FDA's FAERS adverse-event database prompted a multi-year FDA review starting in 2023. That review did not hold up. On January 13, 2026, the FDA closed the review, finding no increased risk of suicidal ideation or behavior across a meta-analysis of 91 placebo-controlled trials (107,910 patients) plus a large healthcare-claims cohort comparing GLP-1 users to SGLT2-inhibitor users (~2.2 million patients). The FDA ordered the suicidal-ideation language removed from the Warnings & Precautions sections of the Saxenda, Wegovy, and Zepbound labels.^[17]

Vision: NAION ("eye stroke") risk

A possible link between semaglutide and a rare optic-nerve condition called non-arteritic anterior ischemic optic neuropathy (NAION) — sometimes described as an "eye stroke" — has been one of the most discussed safety questions of the past two years. Here is where the evidence stands, kept in proportion.

In March 2026, the North American Neuro-Ophthalmology Society (NANOS) and the American Academy of Ophthalmology issued a joint clinical statement. Their measured conclusion: the association is real but observational — drawn from retrospective studies that show an association, not proof of cause. If a true increase exists, it is roughly a 2-fold relative risk and likely lower than the original 2024 study suggested. Crucially, NAION is rare to begin with, so even a doubled relative risk translates to a small absolute risk. The societies recommend shared decision-making, not universal discontinuation, and they specifically advised against automatically stopping the drug.^[18]

What that looks like in absolute numbers: an April 2026 JAMA Ophthalmology target-trial-emulation study followed 102,361 US veterans with type 2 diabetes, comparing semaglutide initiators to those starting an SGLT2 inhibitor. It found a hazard ratio of about 2.33 — but the incidence was roughly 123 per 100,000 person-years on semaglutide versus 67 per 100,000 on SGLT2 inhibitors (about 0.3% vs 0.1% cumulative risk). That is more than double the relative risk, yet still about one additional case per several thousand patients treated.^[19] A September 2025 systematic review and meta-analysis put the pooled estimate at a hazard ratio of about 2.62 (95% CI 1.81–3.80), with risk rising over longer exposure.^[20] In Europe, the EMA's safety committee (PRAC) concluded in June 2025 that NAION is a "very rare" side effect of semaglutide (up to 1 in 10,000) and recommended adding it to the EU product information.^[26]

What changed in July 2026

Annals of Internal Medicine published two independent studies on the same day — the most substantive evidence on this question so far. Both found an elevated relative risk. Both concluded the absolute risk is tiny and that residual confounding is a plausible part of the explanation.

• A US target trial emulation in commercial claims data (adults 18–65 with type 2 diabetes, 2017–2022, more than 80 covariates) found an 18-month risk of ischemic optic neuropathy of 8.5 versus 5.5 per 10,000 compared with SGLT2 inhibitors (risk difference 3.0 per 10,000, 95% CI 0.4–5.7) and 7.8 versus 4.2 per 10,000 compared with DPP4 inhibitors (3.6, 1.1–6.1). In plain terms, that is roughly one extra case for every 2,800 to 3,300 people treated. Events clustered in people over 50 (85%) and in men (70%). The authors flag that NAION-specific diagnostic codes were not available, so the outcome is broader than NAION alone.^[27]
• A Swedish nationwide cohort covering 2013–2024 found anterior ischemic optic neuropathy in 62 of 107,518 GLP-1 agonist initiators versus 64 of 185,898 SGLT-2 inhibitor initiators. One-year risk was 0.04% versus 0.02% (relative risk 1.93, 95% CI 1.00–3.73) and five-year risk 0.12% versus 0.07% (1.69, 0.95–3.01). Both confidence intervals brush against 1.0. Tellingly, when the analysis was restricted to people already taking metformin — a group more similar in diabetes severity — the association shrank substantially (one-year RR 1.40, 0.64–3.05), which the authors read as a sign that some of the signal reflects who takes these drugs rather than the drugs themselves.^[28]

The label picture is not the same everywhere

This is worth knowing if you compare sources across countries. The EMA's safety committee recommended adding NAION to EU product information in June 2025, and Australia's TGA reportedly issued a safety update in July 2026 saying it would follow — we were not able to verify that update against the TGA directly, so treat the Australian detail as provisional. The US label has not changed. The current Wegovy prescribing information, revised June 2026, mentions pulmonary aspiration and postmarketing ileus but contains no NAION language anywhere. That divergence is a regulatory judgment call about how to word a very rare event, not a signal that one regulator has found something the others have not.

Weight regain after discontinuation

This deserves its own section because it's one of the most important limitations:

• STEP 4: Switching to placebo after 20 weeks of semaglutide led to gradual weight regain^[4]
• STEP 1 extension: Participants regained approximately two-thirds of their weight loss within one year of stopping^[5]
• Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed after discontinuation

This doesn't mean semaglutide "doesn't work." It means obesity is a chronic condition, and semaglutide — like medications for hypertension or high cholesterol — requires ongoing use to maintain its effects.

How people use it

Unlike most peptides profiled on Peptide Garden, semaglutide has FDA-approved dosing protocols validated in large clinical trials. These are the clinically established regimens.

FDA-approved dosing — Ozempic (injectable, type 2 diabetes)

FDA-approved dosing — Wegovy (injectable, weight management)

FDA-approved dosing — Rybelsus (oral, type 2 diabetes)

Administration routes

• Subcutaneous injection (Ozempic, Wegovy injectable): Abdomen, thigh, or upper arm. Once weekly. Comes in pre-filled pen — no reconstitution needed.
• Oral tablet (Rybelsus, Wegovy oral): Daily for Rybelsus. Approved in oral form for Wegovy as of December 2025.

Compounded semaglutide: a critical safety distinction

Key differences between FDA-approved and compounded semaglutide:

• Dosing precision: FDA-approved pens deliver exact doses. Compounded vials require manual dose measurement, leading to confusion between mg, mL, and "units" that has caused 5-20x overdoses.
• Salt form: Compounded versions may use semaglutide sodium or acetate, which may have different pharmacological properties than the active ingredient in Ozempic/Wegovy.
• Quality control: FDA-approved products undergo rigorous manufacturing standards. Compounded products have variable quality — the FDA has sent 50+ warning letters to GLP-1 compounders.
• Cost: Compounded semaglutide ($99-$500/month) is significantly cheaper than branded products (Ozempic ~$998/month, Wegovy ~$1,349/month without insurance).

What the 2026 evidence adds

Two studies published in July 2026 sharpen this picture considerably.

The first is a secret-shopper study in JAMA Health Forum. Researchers contacted weight-loss clinics and medical spas in West Virginia and Oklahoma and identified 75 businesses still selling compounded GLP-1 medications after the shortages had ended. Of those, 7 (9.3%) offered oral compounded formulations and 42 (56.0%) offered products combined with B vitamins — neither of which corresponds to any FDA-approved product. Among the supplying compounding facilities the team could verify, 4 of 21 (19.0%) were not licensed to perform sterile compounding at all. That last figure is the one that matters most: these are injectable products, and sterile compounding licensure is the baseline safeguard against contamination. Two caveats worth stating: the data were collected in late 2025, and two states are not a national picture.^[34]

The second is a laboratory analysis in Pharmaceutical Research comparing compounded and "follow-on" semaglutide and liraglutide against the originator products. It found amino acid deletions and additions, unidentified impurities, differences in strength and high-molecular-weight protein content after light exposure, and — using an assay that looks at how immune cells present protein fragments — a distinct set of potentially immunogenic peptides compared with the originator. This is the most concrete mechanistic support yet for the claim that "compounded" is not simply a cheaper version of the same molecule. It is also strictly a lab study: no patients, no clinical immunogenicity outcomes, and the authors themselves call for clinical work. We were not able to confirm who funded it, which is worth flagging because originator manufacturers have an obvious commercial interest in this comparison.^[35]

Legal & regulatory status

As of August 2026:

FDA-approved indications

Semaglutide is an FDA-approved prescription drug with multiple approved indications across three brand names:

In March 2026, the FDA approved Wegovy HD — a higher-dose 7.2 mg formulation — under the Commissioner's National Priority Voucher pathway, with a US launch the following month.^[23]

Nothing changed in the US between late June and mid-August 2026. No new approvals, no new indications, and no approved label supplements for semaglutide in that window. The current Wegovy label, revised June 2026, still carries no NAION warning despite the European, UK and Australian additions described above.

Outside the US

On July 15, 2026, the European Commission granted EU-wide marketing authorisation for the Wegovy pill — once-daily oral semaglutide 25 mg, the first oral GLP-1 receptor agonist approved for weight management in the EU — and for the Wegovy 7.2 mg single-dose pen. The indication is adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, alongside diet and physical activity. Novo Nordisk described this as the fifth regulatory approval of the Wegovy pill worldwide, following the US, UK and UAE, with EU rollout of the higher-dose pen planned for the second half of 2026.^[36] Reported efficacy figures for the pivotal oral-semaglutide trial differ between sources, so we are not quoting a single number until the primary publication can be checked.

Compounding status

The regulatory landscape for compounded semaglutide has changed significantly:

• During the FDA-declared shortage, compounding pharmacies could legally prepare semaglutide
• February 2026: The FDA declared the semaglutide shortage officially ended
• Post-shortage, compounding is only permitted for patients with documented medical needs (e.g., allergy to branded inactive ingredients, specific dosing requirements not available in commercial products)
• The FDA has sent 50+ warning letters to GLP-1 compounders for violations
• Tighter restrictions have reduced supply and increased prices at telehealth providers
• April 2026: The FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulks List, which would close the last route for outsourcing facilities to compound them at scale. As of mid-August 2026 we could not confirm that a final determination has been issued.^[39]
• A July 2026 secret-shopper study found compounded GLP-1 products still widely sold in the two states it sampled, with roughly one in five identified supplying facilities not licensed for sterile compounding^[34]

WADA / USADA status

Semaglutide is not prohibited under WADA anti-doping rules — GLP-1s are not on the 2026 Prohibited List. It has been on WADA's Monitoring Program since 2024, meaning WADA is tracking usage patterns among athletes; for 2026 the Monitoring Program tracks markers of both semaglutide and tirzepatide. Athletes will NOT receive anti-doping violations for semaglutide use. A decision on possible prohibition is expected by the end of 2026 or in 2027, potentially ahead of the LA 2028 Olympics.

Insurance and access

• Most commercial insurance covers semaglutide for the type 2 diabetes indication
• Coverage for weight management is expanding but inconsistent
• Medicare: a temporary CMS demonstration, the GLP-1 Bridge, began July 1, 2026 and offers eligible Part D and MA-PD enrollees roughly $50 per 30-day supply for weight management — the first time Medicare has paid for obesity indications at scale. It sits outside the standard Part D benefit, so copays do not count toward the deductible or the out-of-pocket cap. Published accounts of the program's end date and exact covered-drug list disagree, so check CMS directly rather than a summary
• Manufacturer savings cards can reduce copays to ~$25/month for eligible commercially insured patients
• Without insurance: Ozempic ~$998/month, Wegovy ~$1,349/month, Rybelsus ~$998/month

How semaglutide compares

Semaglutide vs. Tirzepatide (the most common comparison)

The SURMOUNT-5 trial provided the first head-to-head data between semaglutide and tirzepatide — the two dominant GLP-1-based weight loss drugs:^[11]

Tirzepatide achieves greater weight loss in head-to-head comparison. On cardiovascular outcomes, semaglutide still has the more direct evidence: SELECT was placebo-controlled, while tirzepatide's SURPASS-CVOT compared it against dulaglutide — an active comparator that itself reduces cardiovascular events — and met noninferiority rather than superiority. A large 2026 observational cohort has since reported a substantial cardiovascular benefit for tirzepatide against a placebo-proxy comparator, which narrows the gap but is not randomized evidence (see the tirzepatide profile). Semaglutide also has more FDA-approved indications. Both drugs have similar GI side effect profiles. The choice between them is best made with a physician based on individual clinical circumstances.

Semaglutide vs. the peptide evidence standard

To understand what "strong evidence" means, compare semaglutide to a popular research peptide:

This contrast isn't meant to diminish BPC-157 — it's meant to calibrate expectations. When you see a peptide vendor claim their product has "clinical evidence," ask: how many participants? What study design? Published where? The difference between 30 participants in open-label studies and 17,604 in a double-blind RCT is the difference between "interesting signal" and "established fact."